Evogene Ltd.
EVGNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeEvogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. The company carries a $4.9M market cap, placing it firmly in the micro-cap category. It operates through three segments: Agriculture, Human Health, and Industrial Applications.
Market Cap
$4.9M
Beta
0.72
P/E (TTM)
—
P/E (Fwd)
-0.61
EPS (TTM)
$-1.55
EPS (Fwd)
$-0.60
ROE
-182.8%
ROA
-37.5%
Cash
$9.3M
Total Debt
$2.1M
Free CF
-$2.0M
52W Change
-71.2%
Annual Financials
Cash vs Debt
Where EVGN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, EVGN finished 39.34% below its 150-day moving average ($0.61) and 47.14% below its 200-day moving average ($0.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EVGN overbought or oversold?
At the October 20, 2026 close, EVGN's RSI(14) was 40.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $9.3M in cash comfortably exceeding the $2.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$2.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -182.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $930K (2021) to $3.9M (2025), reflecting a 314% increase over the period.
With cash comfortably exceeding debt, EVGN has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Evogene Ltd. and its sector.